Limits...
Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy.

Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, Barriales-Villa R, Castro-Beiras A, Díez J - Eur. Heart J. (2010)

Bottom Line: Significant correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001) and the Spirito's LVH score (r = 0.287, P = 0.006) in HCM patients.These findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM.Further studies are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy.

View Article: PubMed Central - PubMed

Affiliation: Insituto de Investigación Biomédica de A Coruña, Complejo Hospitalario Universitario A Coruña, As Xubias 84, A Coruña, Spain. lorenzo.monserrat.iglesias@sergas.es

ABSTRACT

Aims: Cardiotrophin-1 (CT-1) is a cytokine that induces hypertrophy in cardiomyocytes and is associated with left ventricular hypertrophy (LVH) in hypertensive patients. The objective of this study was to evaluate whether plasma CT-1 is associated with hypertrophic cardiomyopathy (HCM).

Methods and results: The study was performed in 124 patients with HCM. All patients underwent a full clinical evaluation and an echocardiogram. Left ventricular hypertrophy was evaluated by the measurement of the maximal LV wall thickness and the Spirito's LVH score. Plasma CT-1 was measured by an enzyme-linked immunosorbent assay. Compared with controls, patients with HCM exhibited higher (P < 0.001) plasma CT-1 levels. Significant correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001) and the Spirito's LVH score (r = 0.287, P = 0.006) in HCM patients. In addition, the levels of CT-1 were higher (P = 0.02) in patients with severe LVH (maximal LV wall thickness ≥30 mm) than in patients with mild or moderate LVH (maximal LV wall thickness <30 mm).

Conclusions: These findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM. Further studies are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy.

Show MeSH

Related in: MedlinePlus

(A) Direct correlation between plasma CT-1 and maximal left ventricular (LV) wall thickness (y = 0.024x + 18.05) in patients with hypertrophic cardiomyopathy. (B) Direct correlation between plasma cardiotrophin-1 (CT-1) and Spirito's LV hypertrophy score (y = 0.067x + 56.91) in patients with HCM.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3021387&req=5

EHQ400F3: (A) Direct correlation between plasma CT-1 and maximal left ventricular (LV) wall thickness (y = 0.024x + 18.05) in patients with hypertrophic cardiomyopathy. (B) Direct correlation between plasma cardiotrophin-1 (CT-1) and Spirito's LV hypertrophy score (y = 0.067x + 56.91) in patients with HCM.

Mentions: Cardiotrophin-1 was higher (P = 0.02) in patients with severe LVH (maximal LV wall thickness ≥30 mm) than in patients with mild o moderate LVH (maximal LV wall thickness <30 mm; Figure 2). Direct correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001; Figure 3A), and Spirito's score (r = 0.287, P = 0.006; Figure 3B). In addition, CT-1 was directly correlated with wall thickness in 9 out of the 14 LV segments evaluated and with the maximal thickness at basal, mid-ventricular, and apical levels, as well as with LV and left atrial dimensions (Table 2). The associations of CT-1 with maximal LV wall thickness and Spirito's score remained significant when we adjusted for the influence of these echocardiographic confounding factors. No significant correlations were found between CT-1 levels and sex, presence of non-sustained ventricular tachycardia, left ventricular outflow tract obstruction, previous syncope, abnormal blood pressure response on exercise test, or previous atrial fibrillation. Cardiotrophin-1 values were non-significantly higher in patients with more sudden death risk factors, which could be explained by the association of CT-1 values with the presence of severe hypertrophy. The group of six patients with left ventricular systolic dysfunction showed also higher CT-1 values than patients without systolic dysfunction, but this difference was not statistically significant (Table 3).Figure 2


Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy.

Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, Barriales-Villa R, Castro-Beiras A, Díez J - Eur. Heart J. (2010)

(A) Direct correlation between plasma CT-1 and maximal left ventricular (LV) wall thickness (y = 0.024x + 18.05) in patients with hypertrophic cardiomyopathy. (B) Direct correlation between plasma cardiotrophin-1 (CT-1) and Spirito's LV hypertrophy score (y = 0.067x + 56.91) in patients with HCM.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3021387&req=5

EHQ400F3: (A) Direct correlation between plasma CT-1 and maximal left ventricular (LV) wall thickness (y = 0.024x + 18.05) in patients with hypertrophic cardiomyopathy. (B) Direct correlation between plasma cardiotrophin-1 (CT-1) and Spirito's LV hypertrophy score (y = 0.067x + 56.91) in patients with HCM.
Mentions: Cardiotrophin-1 was higher (P = 0.02) in patients with severe LVH (maximal LV wall thickness ≥30 mm) than in patients with mild o moderate LVH (maximal LV wall thickness <30 mm; Figure 2). Direct correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001; Figure 3A), and Spirito's score (r = 0.287, P = 0.006; Figure 3B). In addition, CT-1 was directly correlated with wall thickness in 9 out of the 14 LV segments evaluated and with the maximal thickness at basal, mid-ventricular, and apical levels, as well as with LV and left atrial dimensions (Table 2). The associations of CT-1 with maximal LV wall thickness and Spirito's score remained significant when we adjusted for the influence of these echocardiographic confounding factors. No significant correlations were found between CT-1 levels and sex, presence of non-sustained ventricular tachycardia, left ventricular outflow tract obstruction, previous syncope, abnormal blood pressure response on exercise test, or previous atrial fibrillation. Cardiotrophin-1 values were non-significantly higher in patients with more sudden death risk factors, which could be explained by the association of CT-1 values with the presence of severe hypertrophy. The group of six patients with left ventricular systolic dysfunction showed also higher CT-1 values than patients without systolic dysfunction, but this difference was not statistically significant (Table 3).Figure 2

Bottom Line: Significant correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001) and the Spirito's LVH score (r = 0.287, P = 0.006) in HCM patients.These findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM.Further studies are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy.

View Article: PubMed Central - PubMed

Affiliation: Insituto de Investigación Biomédica de A Coruña, Complejo Hospitalario Universitario A Coruña, As Xubias 84, A Coruña, Spain. lorenzo.monserrat.iglesias@sergas.es

ABSTRACT

Aims: Cardiotrophin-1 (CT-1) is a cytokine that induces hypertrophy in cardiomyocytes and is associated with left ventricular hypertrophy (LVH) in hypertensive patients. The objective of this study was to evaluate whether plasma CT-1 is associated with hypertrophic cardiomyopathy (HCM).

Methods and results: The study was performed in 124 patients with HCM. All patients underwent a full clinical evaluation and an echocardiogram. Left ventricular hypertrophy was evaluated by the measurement of the maximal LV wall thickness and the Spirito's LVH score. Plasma CT-1 was measured by an enzyme-linked immunosorbent assay. Compared with controls, patients with HCM exhibited higher (P < 0.001) plasma CT-1 levels. Significant correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001) and the Spirito's LVH score (r = 0.287, P = 0.006) in HCM patients. In addition, the levels of CT-1 were higher (P = 0.02) in patients with severe LVH (maximal LV wall thickness ≥30 mm) than in patients with mild or moderate LVH (maximal LV wall thickness <30 mm).

Conclusions: These findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM. Further studies are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy.

Show MeSH
Related in: MedlinePlus